William Haegele Joins Propedix Board as Independent Director Driving Growth

Propedix Inc. Welcomes William Haegele to Its Board of Directors

On June 4, 2025, Propedix Inc., a prominent company specializing in anti-infective dermatological treatments, announced a key addition to its leadership team with the appointment of William Haegele as the first Independent Director of the Board. Haegele's strategic insight will be pivotal in steering Propedix's initiatives as the company aims for robust growth and innovation.

A Pioneering Background in Life Sciences

William Haegele brings a wealth of experience, particularly from his tenure as a retired partner at KPMG where he honed his skills in corporate governance and risk management. His extensive background includes various leadership roles within life sciences organizations, equipping him with the necessary tools to contribute meaningfully to Propedix's strategic direction. Recognized for his innovative mindset and comprehensive understanding of the biotech landscape, Haegele's expertise aligns with the company's agenda to launch groundbreaking products.

Focus on Dermatological Innovations

Propedix's flagship product, Dryello™, is on the verge of its commercial launch, designed as an over-the-counter treatment for athlete's foot – also known as tinea pedis. This product aims to effectively treat and prevent the fungal infection and its associated symptoms. Haegele’s involvement is expected to enhance not only governance oversight but to also foster robust discussions around future product development.

“We are thrilled to welcome Bill to our Board of Directors,” expressed Niv Caviar, CEO of Propedix. “His visionary approach and extensive expertise in life sciences directly resonate with our goals and ambitions at Propedix. We firmly believe that with Bill on our team, we will elevate our company to new heights.”

Enhancing Corporate Governance

In his new role, Haegele will oversee the company's financial and accounting functions while also providing governance in the corporate realm. His experience is set to play a crucial role in strategically guiding Propedix as it introduces innovative dermatological solutions to the market. Haegele's remarks upon joining the board reflect his enthusiasm: “I am honored to join the Propedix team and look forward to contributing to the company's growth and success. I am confident that the management team's decades of experience in developing and commercializing dermatological technologies will establish Propedix as a leader in innovative biopharma delivery solutions.”

Committed to Patient-Centric Solutions

Established as a leading biopharma and consumer health company, Propedix is dedicated to enhancing the quality of life of patients through innovative topical dermatology and anti-infective treatments. With a strong focus on research and development, Propedix is committed to creating clinically tested, effective solutions for fungal conditions. Propedix is known for its propriety delivery and formulation technology and is actively expanding its portfolio of antifungal treatments.

Dryello™ — the upcoming flagship product — not only addresses athlete’s foot but is also formulated to alleviate symptoms such as itching, perspiration, maceration, and scaling. The company plans to unveil compelling clinical data supporting Dryello's efficacy upon its launch in early summer, aiming to establish a new standard in treatment for fungal infections.

As Propedix continues to solidify its presence in the dermatological market, the appointment of William Haegele to its Board signals a strategic commitment towards growth, innovation, and governance excellence. The team is optimistic that under his guidance, the potential for expansion within the biopharma sector is limitless.

In summary, the integration of William Haegele into Propedix's Board of Directors marks a strategic move towards enhancing governance and driving forward-thinking initiatives aimed at solidifying its position as a leader in innovative dermatological solutions.